GSK plc

NYSE:GSK

Drug Manufacturers - General

Healthcare
$48.58 -2.56%

-$1.34 today

Market cap
$97.53B
Beta
0.29
P/E (TTM)
13.3
EPS (TTM)
$1.45
Dividend yield
3.48%
52W Low $35.45High $61.70

Volume 2.02M

Average 4.07M

GSK Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

GSK plcNYSE: GSK

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of £224.81M fell 80.6% year over year, behind the -34.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 51.4% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Depreciation & amortization amounted to 7.1% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -80.6% toward the trailing-twelve-month pace of -34.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
£224.81M-51.4% QoQ
Last fiscal yearDec 2025
£2.31B-9.3% YoY
LTMJun 2026
£2.21B-34.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-80.6%——
1 year-9.3%——
3-year CAGR+2.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

GBP · from the cash flow

Latest · FY2025
2.31B GBP
Year-over-year change
-9.3%
4-year CAGR
+2.2%

Depreciation & Amortization vs competitors

How GSK compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.0% is the lowest of 10, against a peer median of +10.9%.
  • Depreciation & amortization amounts to 6.7% of revenue for GSK, versus a peer median of 10.1%.
GSK Competitors
Depreciation & Amortization for GSK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 27.16B DKK+69.6%+44.0%8.2%
JNJJohnson & JohnsonLTM Sep 2026$8.09B USD+9.5%+2.5%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$6.72B USD+45.9%+14.3%10.1%
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B USD+29.8%+3.0%10.3%
SNYSanofiLTM Jun 2026€5.88B EUR+22.9%+22.2%12.0%
NVSNovartis AGLTM Jun 2026$5.34B USD-11.0%-7.2%9.6%
AMGNAmgen Inc.LTM Jun 2026$4.67B USD-15.5%+14.8%12.2%
GSKGSK plcLTM Jun 2026£2.21B GBP-34.0%+2.5%6.7%
LLYEli Lilly and CompanyLTM Jun 2026$2.1B USD+10.9%+9.5%2.6%
Peer median (excluding GSK) —+10.9%+9.5%10.1%

Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.52B5.49B6.13B2.95B5.59B
Depreciation & Amortization2.12B2.15B2.29B2.55B2.31B
Deferred Income Tax0(965.72M)(1.08B)00
Stock-Based Compensation343M00344M0
Change in Working Capital1.39B(1.67B)(1.06B)2.09B(608.37M)
Accounts Receivables(1.16B)(758.78M)(806.74M)340M0
Inventory51M(331.35M)(527.05M)(294M)0
Accounts Payables0608.5M(18.65M)00
Other Working Capital2.5B(1.19B)288.39M2.04B(608.37M)
Other Non-Cash Items584M3.16B1.61B(1.38B)(153.41M)
Operating Cash Flow7.95B8.16B7.89B6.55B7.14B
Capital Expenditures(2.65B)(1.41B)(1.63B)(2.98B)(1.32B)
Acquisitions (Net)185M(3.79B)(1.72B)1.37B(4.37B)
Purchases of Investments0(177.38M)(152.9M)0(89.98M)
Sales of Investments18M294.4M2.37B21M195.62M
Other Investing Activities(1.03B)(4.43B)14.92M(1.22B)1.46B
Investing Cash Flow(1.78B)(10.88B)(2.4B)(1.23B)(5.72B)
Debt Repayment(2B)(5.69B)(2.95B)(1.17B)1.47B
Common Stock Issued21M30.79M12.43M20M14.67M
Common Stock Repurchased00000
Dividends Paid(4B)(4.27B)(2.79B)(2.44B)(2.51B)
Other Financing Activities(1.61B)11.98B(341.84M)(1.14B)(573.16M)
Financing Cash Flow(7.59B)2.05B(6.07B)(4.73B)(1.59B)
Effect of Forex Changes(29M)(637.97M)(153.84M)(54M)(32.94M)
Net Change in Cash(1.44B)(1.31B)(735.58M)545M(206.06M)
Free Cash Flow5.3B6.75B6.26B3.57B5.82B

GSK plc

NYSE:GSK

Intrinsic Alpha fair value

Locked

Current Price

$48.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.